BioNano reported Q3 2026 revenue of $8.3 million, up 12%, and record flow-cell sales of 9,870 units, up 18%. Adjusted gross margin reached 48%, and full-year 2026 revenue guidance remained $31 million to $33 million.
BNGO · Bionano Genomics, Inc. · Documents
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, we determined that there is substantial doubt about our ability to continue as a going concern within 12 months after the date that the financial statements included in this Quarterly Report are issued.”View the 10-Q filed Nov 10, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Bionano Genomics reported revenue of $23.1 million, up 13%, and a $22.2 million net loss for the nine months ended September 30, 2026. It faces substantial doubt about going concern and expects additional capital in the very near term.
Bionano Genomics reported third-quarter revenue of $8.3 million, up 12% from $7.4 million, and gross margin of 48%, up from 46%. It reiterated full year 2026 revenue guidance of $31 to $33 million.
Bionano Genomics, Inc. established a replacement shelf registration for up to $400,000,000 and disclosed an additional $3,941,645.77 of securities sold under its prior registration statement.
Bionano Genomics, Inc. is registering up to 1,332,632 shares issuable upon exercise of outstanding warrants, replacing an expiring registration statement so warrant exercises remain covered. Full exercise would generate approximately $90 million for general corporate purposes.